Key Highlights
- FFL Partners invests in Apex Infusion, a leading ambulatory infusion therapy provider.
- Apex Infusion focuses on high-quality care for patients in home and ambulatory settings.
- Growth plans include geographic expansion and strategic acquisitions.
Source: Business Wire
Notable Quotes
- “Apex Infusion is a well-operated infusion provider focused on delivering a high-quality patient and doctor experience.” — Karen Winterhof, Partner at FFL
- “We look forward to accelerating our growth in partnership with FFL.” — Moussie Hailemariam, Chief Executive Officer at Apex Infusion
- “We remain committed to delivering the same high-quality, reliable care that our patients have come to expect from Apex Infusion.” — Rick Smith, Executive Chairman at Apex Infusion
- “We believe there’s a significant greenfield de novo and acquisition opportunity, and we expect to deploy more capital to support Apex’s M&A strategy.” — Chris Harris, Managing Partner at FFL Partners
SoHC's Take
The investment by FFL Partners in Apex Infusion marks a strategic move to expand and strengthen the ambulatory infusion therapy sector. With FFL’s extensive experience in healthcare and tech-enabled services, this partnership is poised to enhance Apex Infusion’s capabilities and reach. The planned geographic expansion and strategic acquisitions will likely position Apex Infusion as a leading player in the specialty infusion market, meeting critical patient needs while optimizing cost efficiency for payors. The collaborative effort between FFL and Apex Infusion’s management team underscores a commitment to quality care and growth, setting a strong foundation for future success.
